These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 72846)

  • 21. Effects of tranexamic acid on fibrinolysis, fibrinogenolysis and amidolysis.
    Takada A; Makino Y; Takada Y
    Thromb Res; 1986 Apr; 42(1):39-47. PubMed ID: 3705023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin.
    Juhan I; Calas MF; Buonocore M; Mathieu P; Isnard G; Cazenave B; Serradimigni A
    Thromb Haemost; 1979 Oct; 42(3):945-54. PubMed ID: 315625
    [No Abstract]   [Full Text] [Related]  

  • 23. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
    Gram J
    Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
    Lijnen HR; Soria J; Soria C; Collen D; Caen JP
    Thromb Haemost; 1984 Feb; 51(1):108-9. PubMed ID: 6539000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Origin of urinary fibrin/fibrinogen degradation products in glomerulonephritis.
    Ekberg M; Pandolfi M
    Br Med J; 1975 Apr; 2(5961):17-9. PubMed ID: 48398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Coagulation and fibrinolysis in interstitial lung diseases].
    Tałałaj J; Chyczewska E
    Pneumonol Alergol Pol; 1999; 67(3-4):146-50. PubMed ID: 10497448
    [No Abstract]   [Full Text] [Related]  

  • 27. Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells.
    Sitter T; Spannagl M; Schiffl H; Held E; van Hinsbergh VW; Kooistra T
    Nephrol Dial Transplant; 1995; 10(5):677-83. PubMed ID: 7566582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study of the function of coagulation, fibrinolysis and pulmonary vascular endothelium before and after experimental pulmonary thromboembolism in rabbits].
    Pang BS; Wang C; Luo Q; Zhang LM; Zhu M; Mao YL; Huang XX; Guo WJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jun; 27(6):381-4. PubMed ID: 15256085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Blood coagulation mechanism from the viewpoint of molecular biochemistry: Mechanism of fibrinolysis].
    Matsuda T
    Rinsho Byori; 1985 Sep; 33(9):982-8. PubMed ID: 2416968
    [No Abstract]   [Full Text] [Related]  

  • 31. [Late results following fibrinolysis therapy of venous thromboses].
    Breddin HK
    Internist (Berl); 1984 Feb; 25(2):102-7. PubMed ID: 6368451
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of coagulation in renal disease.
    MacDonald MK; Clarkson AR; Davison AM
    Perspect Nephrol Hypertens; 1973; 1 Pt 2(0):809-28. PubMed ID: 4807810
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of urokinase therapy in patients with glomerulonephritis and nephrotic syndrome. Trial at multiple institutes in Japan].
    Tomura S; Takeuchi J; Tanaka K
    Nihon Jinzo Gakkai Shi; 1984 Jan; 26(1):97-121. PubMed ID: 6376892
    [No Abstract]   [Full Text] [Related]  

  • 34. The coagulation and fibrinolysis systems and atherosclerosis.
    Tanaka K; Sueishi K
    Lab Invest; 1993 Jul; 69(1):5-18. PubMed ID: 8331898
    [No Abstract]   [Full Text] [Related]  

  • 35. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
    Colick JA; Fisher LM
    Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
    [No Abstract]   [Full Text] [Related]  

  • 36. Determination of tissue type plasminogen activator in the glomeruli of patients with IgA nephropathy.
    Garcia G; Miura M; Nomoto Y; Sakai H
    Tokai J Exp Clin Med; 1989 Apr; 14(2):131-7. PubMed ID: 2517871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha 2-plasmin inhibitor deficiency.
    Lipinski B; Gurewich V
    Lancet; 1979 Feb; 1(8111):329. PubMed ID: 84984
    [No Abstract]   [Full Text] [Related]  

  • 40. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome.
    Nevard CH; Jurd KM; Lane DA; Philippou H; Haycock GB; Hunt BJ
    Thromb Haemost; 1997 Dec; 78(6):1450-5. PubMed ID: 9423793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.